BACKGROUND
==========

Glioblastoma multiforme (GBM) is a primary brain tumour which is characterized by a rapidly growing mass that varies in size and shape, and accounts for 70% of all primary brain tumours. It is classified by the WHO as a highly malignant tumour^\[[@b1-954-1-5901-1-10-20180911]--[@b3-954-1-5901-1-10-20180911]\]^. Although GBM may present as multiple lesions, it is usually a just single mass^\[[@b2-954-1-5901-1-10-20180911]\]^. Headache, vomiting and seizure are the most common presentations^\[[@b2-954-1-5901-1-10-20180911],[@b4-954-1-5901-1-10-20180911],[@b5-954-1-5901-1-10-20180911]\]^. The GBM can double in size in 2 days to several weeks, which gives it a dire prognosis, with a median survival time of 9.9 months if treated with surgery and radiotherapy with or without chemotherapy. It is twice as common in white as in black patients^\[[@b2-954-1-5901-1-10-20180911],[@b5-954-1-5901-1-10-20180911]--[@b7-954-1-5901-1-10-20180911]\]^ and is also slightly more frequent in males than females. It is often located in the supratentorial region of the brain with extensive necrosis^\[[@b5-954-1-5901-1-10-20180911],[@b6-954-1-5901-1-10-20180911]\]^.

About 5% of patients with GBM have a family history, and some cases are linked to rare syndromes, such as Li-Fraumeni syndrome, neurofibromatosis I and II, or Turcot's syndrome^\[[@b6-954-1-5901-1-10-20180911]\]^. If the GBM tumour involves the corpus callosum, then it is called 'butterfly glioma', and usually metastasizes to the occipital and temporal lobes bilaterally^\[[@b2-954-1-5901-1-10-20180911],[@b6-954-1-5901-1-10-20180911]\]^. Good prognostic features for GBM are younger age, lateral tumour localization, complete macroscopic resection, and abundant giant cells (gigantocellular glioblastoma)^\[[@b7-954-1-5901-1-10-20180911],[@b8-954-1-5901-1-10-20180911]\]^. The brain MRI may not show a typical mass. Indeed, deceiving features of a demyelinating process may be seen. Hence GBM should be considered in a middle-aged patient with an atypical presentation who does not respond to the usual treatment for the suspected condition^\[[@b9-954-1-5901-1-10-20180911]\]^. GBM can also occur in octogenarians^\[[@b10-954-1-5901-1-10-20180911]\]^. If GBM is suspected in a patient where resection is not feasible, a fine needle biopsy is recommended to reduce trauma^\[[@b11-954-1-5901-1-10-20180911],[@b12-954-1-5901-1-10-20180911]\]^. GBM can spread directly to adjacent parts of the brain or extracranially via the CSF^\[[@b13-954-1-5901-1-10-20180911]\]^. Both GBM and its treatment can cause neurological, cognitive or psychiatric symptoms^\[[@b14-954-1-5901-1-10-20180911]\]^.

CASE REPORT
===========

A 53-year-old woman presented to her primary care physician complaining of feeling anxious, with panic at times. She was having difficulty finding words and had bilateral hand and wrist pain, which had largely improved although there was still some lack of coordination. She also had trouble getting out of the bed and getting dressed. However, she denied headache, nausea or vomiting. The patient described her anxiety symptoms as insomnia, shortness of breath and feeling 'closed in'. She had experienced these symptoms for a few years but they had got worse over the past month. She denied suicidal and homicidal ideation. The patient felt more comfortable sleeping during the day, but this caused her to stay up late at night. She had a past medical history of allergic rhinitis, asthma, hyperglycaemia and hyperlipidaemia. She had a positive family history of anxiety. Physical examination showed normal vital signs, mild nasal congestion, quiet and clear speech, possible mild bilateral thenar atrophy, a mildly positive Phalen's test, and a negative Tinel sign. Mild left facial asymmetry was also noted. Electromyography was normal.

Two days later, the patient presented to the emergency department complaining of progressive left-sided weakness and difficulty in speech. A CT scan of the head to rule out stroke surprisingly showed a mass in the right frontal lobe. MRI confirmed the presence of this mass which extended to the corpus callosum. The mass measured 5.7 cm by 3.8 cm ([Fig. 1](#f1-954-1-5901-1-10-20180911){ref-type="fig"}). CT scans of the chest, abdomen and pelvis were negative for any metastases.

A right frontal stereotactic craniotomy revealed a multicystic, vascular, necrotic mass which was soft in many areas. Frozen sections and biopsy slides ([Fig. 2](#f2-954-1-5901-1-10-20180911){ref-type="fig"}) showed an infiltrating astrocytic tumour with necrosis, microvascular proliferation, and brisk mitotic activity. The tumour cells were strongly immunoreactive to GFAP, and negative for Cam 5.2 and IDH1 R132H mutant antibody. Neurofilament immunostaining highlighted the infiltrating nature of this tumour. P53 immunostaining showed nuclear expression in a minor subset of the tumour cells. All immunostaining was performed with appropriate controls on separate slides. The final diagnosis was GBM of the brain.

DISCUSSION
==========

The first case of GBM was reported in 1880 by Bradley^\[[@b13-954-1-5901-1-10-20180911]\]^. GBM is one of the deadliest adult tumours and has a grave prognosis^\[[@b1-954-1-5901-1-10-20180911],[@b2-954-1-5901-1-10-20180911]\]^. Although it usually presents as a supratentorial tumour, rare cases involving the brainstem and cerebellum have been reported^\[[@b9-954-1-5901-1-10-20180911],[@b10-954-1-5901-1-10-20180911]\]^. Owing to its shape on MRI, which is often described as a ring-enhancing lesion, GBM is sometimes misdiagnosed as an infection or inflammatory process^\[[@b1-954-1-5901-1-10-20180911],[@b9-954-1-5901-1-10-20180911]\]^. GBM is highly metastatic via CSF or spread to adjacent regions^\[[@b1-954-1-5901-1-10-20180911],[@b13-954-1-5901-1-10-20180911]\]^. In the present case, only a single large right frontal mass was identified, with all other screening for satellite lesions being negative. The corpus callosum was involved in this case, but no hydrocephalus or raised intracranial pressure was detected. The swift progression of the patient's symptoms might have been due to rapid growth of the GBM mass. Previous studies have shown that it can take from only 2 days to several weeks for the tumour to double in size^\[[@b7-954-1-5901-1-10-20180911]\]^. Patients survival time is also related to tumour doubling time^\[[@b7-954-1-5901-1-10-20180911],[@b8-954-1-5901-1-10-20180911]\]^. Patients with glioma can exhibit psychiatric symptoms, such as personality and behavioural changes, hallucinations, mood issues or even psychosis^\[[@b14-954-1-5901-1-10-20180911]\]^. In the present case, the patient's initial complaints of anxiety, left-hand lack of coordination (which developed into left-hand weakness) and difficulty in speech were unlike the usual symptoms of brain tumour patients (early morning headache, vomiting or vision disturbance) and more like those of motor neuron disease (MND). However, the patient's EMG result ruled out MND and a CT scan 2 days later revealed the GBM mass in the right frontal lobe. The patient is still alive until this moment.

CONCLUSION
==========

A careful history taking and physical examination of patients with atypical neurological, cognitive or psychiatric symptoms that do not conform with known neurological or psychiatric disorders along with meticulous review of any radiological tests will help early detection of serious tumours. Neurologists should always keep GBM in mind, especially when a patient presents with unusual symptoms that do not suggest well-known neurological conditions.
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![Magnetic resonance imaging clearly shows the right frontal lobe mass extending to the corpus callosum](954_Fig1){#f1-954-1-5901-1-10-20180911}

![Histopathology: (1) H&E stain reveals the tumour with necrosis; (2) GFAP immunostaining is positive for tumour cells; a blood vessel with negative staining shows microvascular proliferation; (3) MIB-1 immunostaining of numerous tumour cells. Molecular information: MIB proliferation index 20%. IDH1 R123H (IHC): negative. IDH1 (NGS): negative; EGFRvIII mutation: negative; MGMT promoter methylation: negative](954_Fig2){#f2-954-1-5901-1-10-20180911}
